Acquisitions, Licensing and Other Arrangements - Kinnate Acquisition (Details) - USD ($) $ / shares in Units, $ in Thousands |
1 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Apr. 30, 2025 |
Apr. 30, 2024 |
Jun. 30, 2025 |
Dec. 31, 2024 |
|
| Asset acquisition | ||||
| Exarafenib milestone contingent consideration | $ 3,402 | $ 3,214 | ||
| Operating lease liabilities | 710 | $ 900 | ||
| CVR Agreement | Kinnate CVR holders | ||||
| Asset acquisition | ||||
| Exarafenib milestone contingent consideration | $ 3,200 | 3,400 | ||
| Kinnate | ||||
| Asset acquisition | ||||
| Asset acquisition, share price (in dollars per share) | $ 2.5879 | |||
| Total purchase consideration | $ 126,400 | |||
| Kinnate | Kinnate CVR holders | ||||
| Asset acquisition | ||||
| Contingent consideration | 600 | |||
| Contingent consideration liability, current | $ 0 | |||
| Kinnate | CVR Agreement | Kinnate CVR holders | ||||
| Asset acquisition | ||||
| Percentage share from potential milestone | 100.00% | |||
| Cash received from milestone payments | $ 30,500 | |||